TAVI for aortic regurgitation – India's first case with Corevalve Evolut R  by Gopalamurugan, A.B. et al.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 4 – s 7
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier.com/locate/ihjCase Report
TAVI for aortic regurgitation – India's first case with
Corevalve Evolut RA.B. Gopalamurugan a,*, K. Murali b, B. Jyotsana c, A. Jacob d, V.V. Bashi e
aChief of Department of Percutaneous Valves, ICAAD, India
bHead of Department of Interventional Radiology, MIOT Hospitals, Chennai, India
cDepartment of Cardiac Anaesthesiology, MIOT Hospitals, Chennai, India
dChief of Cardiac Anaesthesiology, ICAAD, India
eChief of Department of Cardiothoracic and Vascular Surgery, ICAAD, Indiaa r t i c l e i n f o
Article history:
Received 22 January 2016
Accepted 22 March 2016






a b s t r a c t
Transcatheter Aortic Valve Implantation (TAVI) is a well-described treatment for symptom-
atic calciﬁc severe aortic stenosis. However, TAVI technology is being increasingly used
around the world to treat selected cases of severe aortic regurgitation (AR). One of the main
limitations of using TAVI technology for AR is the lack of calciﬁcation, which is common in
such cases. This makes anchoring of a TAVI prosthesis to the aortic annulus difﬁcult and
risks displacement or embolization. However, with the availability of recapturable and
repositionable TAVI technologies, these limitations have been overcome to a large extent.
This is the ﬁrst Corevalve Evolut R device that was used in India and the ﬁrst TAVI to treat AR
in India.
# 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. IntroductionTranscatheter Aortic Valve Implantation (TAVI) is a well-
described treatment for symptomatic calciﬁc severe aortic
stenosis. However, TAVI technology is being increasingly used
around the world to treat selected cases of severe aortic
regurgitation (AR). One of the main limitations of using TAVI
technology for AR is the lack of calciﬁcation, which is common
in such cases. This makes anchoring of a TAVI prosthesis to
the aortic annulus difﬁcult and risks displacement or* Corresponding author at: Department of Percutaneous Valves, Inst
Hospital, Chennai 600026, India. Tel.: +91 44 2000 2001.
E-mail address: gopalamurugan@gmail.com (A.B. Gopalamurugan)
http://dx.doi.org/10.1016/j.ihj.2016.03.022
0019-4832/# 2016 Cardiological Society of India. Published by Elsevier
(http://creativecommons.org/licenses/by-nc-nd/4.0/).embolization. However, with the availability of recapturable
and repositionable TAVI technologies, these limitations have
been overcome to a large extent. This is the ﬁrst Corevalve
Evolut R device that was used in India and the ﬁrst TAVI to
treat AR in India.
2. Case reportA 45-year-old man, awaiting liver transplantation, suffered
aortic valve (AV) endocarditis 9 months previously, which wasitute for Cardiac and Advanced Aortic Disorders (ICAAD), SIMS
.
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mobile chronic vegetation attached to his AV leaﬂet. He had
portal hypertension, previous upper gastrointestinal bleed
from varices, and hypersplenism, with a platelet count of
45,000/mL, hemoglobin of 8 g/dl, and an international normal-
ized ratio of 2.0. Local heart team discussions led to
contemplating TAVI to treat his severe AR before liver
transplantation. Three blood cultures showed no growth of
organisms.
Echocardiogram showed severe AR and a 1 cm highly
mobile hyperechoic mass attached to his AV (Fig. 1). Gated
cardiac CT scan showed unobstructed coronaries, no calciﬁ-
cation of the aortic root or AV, and good caliber peripheral
vessels for a transfemoral delivery of TAVI prosthesis. The
planwas to squash the vegetation alongwith the valve leaﬂet
behind the TAVI prosthesis using a repositionable TAVI
device. A Corevalve Evolut R was chosen, which has the
capability of resheathing and recapturing the device and
thereby allowing redeployment if optimal positioning and
outcome was not achieved.
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Fig. 1 – TOE showing a 1 cm mobile vegetation attached to th
[(Fig._2)TD$FIG]
Fig. 2 – Fluoroscopy image of carotid filters in each internal caro
vegetation.As embolization of the chronic vegetation was a major
concern; two carotid artery ﬁlters were positioned, one in each
internal carotid artery before crossing the AV (Fig. 2). The TAVI
procedure was performed in the standard way using 3D
transesophageal echocardiogram (TOE) guidance. During the
valve deployment, the valve slipped out of the annulus twice
into the ascending aorta due to lack of calciﬁcation and
hyperdynamic left ventrice contraction. The Evolut R device
allowed resheathing and repositioning on these occasions.
During these attempts, the vegetation was monitored
throughout with TOE and the vegetation did not embolize.
At the third attempt, rapid ventricular pacing was undertaken,
which completely abolished cardiac output and the valve was
released at the optimal position trapping the vegetationwithin
the aortic sinus along with the aortic leaﬂet (Figs. 3 and 4).
There was no AR on aortography and on TOE. There were no
complications and the patient was discharged home on day 3
of the procedure. The patient was discharged on Clopidogrel
75 mg OD. The patient subsequently had a successful liver
transplantation after stopping Clopidogrel for ﬁve days beforee aortic valve leaflet causing severe aortic regurgitation.
tid artery to prevent cerebral embolization of mobile
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Fig. 3 – Panel A: Start of TAVI deployment showing the flaring of the TAVI valve prosthesis in the left ventricular outflow tract
(LVOT) and the lower border of pigtail catheter and aortography showing the valve deployment site at the aortic annulus level
(Fig. 4, PanelA). Panel B: Dislodgement of the TAVI prosthesis during deployment toward the ascending aorta; note that the lower
border of the prosthesis is above the lower border of the pigtail, which marks the aortic annulus level. Panel C: TAVI prosthesis
being resheathed in the ascending aorta resulting in partial recapturing of the prosthesis. Panel D: Further resheathing of the
device leading to complete recapture of the device allowing for redeployment. Panel E: TAVI prosthesis redeployed in the
preferred location ready to be fully released after which no resheathing or recapture is possible. Panel F: TAVI prosthesis
completely released in optimal position as marked by the lower end of the pigtail, which was left in this case until full release.
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Fig. 4 – Panel A: TOE at the start of TAVI deployment showing the flaring of the TAVI valve prosthesis in the LVOT and the
mobile mass along with the aortic leaflet behind the flaring prosthesis. Panel B: Further deployment of the TAVI prosthesis
has squashed the leaflet along with the vegetation behind the TAVI prosthesis. Panel C: TOE after full release of the valve at
optimal position, no residual mobile mass and no aortic regurgitation.
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Fig. 5 – Follow-up transthoracic echocardiogram at two months showing no aortic regurgitation and no mobile mass attached
to the prosthesis.
i n d i a n h e a r t j o u rn a l 6 8 ( 2 0 1 6 ) s 4 – s 7 S7surgery and substituting it with lowmolecular weight heparin
until the day before liver transplantation. He was discharged
after transplantation with Clopidogrel 75 mg OD. At two
months follow-up, the patientwas asymptomaticwith normal
TAVI prosthetic function on echocardiogram with no AR and
no visible vegetation (Fig. 5). The patient had no evidence of
infection or active inﬂammation.
3. DiscussionThis case demonstrates the feasibility and acute outcome of
TAVI for AR and the beneﬁt of having a recapturable and
repositionable TAVI prosthesis. It also has shown for
the ﬁrst time that sterile vegetations with appropriateanatomy may not be an absolute contraindication for TAVI.
To our knowledge, this is the ﬁrst human case to demon-
strate this.
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